Randomized trial · people
Dulaglutide lowered major cardiovascular events (HR 0.88) in REWIND
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a large, long trial of older adults with type 2 diabetes, dulaglutide led to fewer major cardiovascular events than placebo, but gut side effects were more common and overall deaths did not clearly differ.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 9901
- Published
- 2019
- Journal
- Lancet
What they tested
Does adding weekly dulaglutide to usual diabetes treatment lower the rate of heart attacks, strokes and cardiovascular deaths in people with type 2 diabetes?
How the study was done
A randomized, double-blind, placebo-controlled trial in 9901 adults aged at least 50 with type 2 diabetes who had either a past cardiovascular event or cardiovascular risk factors, run at 371 sites in 24 countries. Participants got a weekly injection under the skin of dulaglutide 1.5 mg or placebo (a dummy shot) and were followed for a median of 5.4 years.

Model. Individual results vary.
What they found
The main outcome was a first non-fatal heart attack, non-fatal stroke or death from cardiovascular causes. It happened in 594 people (12.0%) on dulaglutide versus 663 (13.4%) on placebo, or 2.4 versus 2.7 per 100 person-years, giving a hazard ratio (a measure of relative risk over time) of 0.88 (95% CI 0.79-0.99). Death from any cause did not clearly differ: 536 (10.8%) versus 592 (12.0%), hazard ratio 0.90 (95% CI 0.80-1.01). Gut side effects were more common on dulaglutide, reported by 2347 people (47.4%) versus 1687 (34.1%) on placebo.
What it doesn’t show
Only one dose, 1.5 mg weekly, was tested, and only in people aged 50 or older with type 2 diabetes and cardiovascular disease or risk factors. The trial was funded by Eli Lilly and Company.
The paper
Gerstein et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019.
The compound
More studies on Dulaglutide
- Mazdutide beat dulaglutide on HbA1c and weight at 28 weeksRandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeksRandomized trial · people · 2022
- Dulaglutide cut HbA1c and weight less than semaglutide in SUSTAIN 7Randomized trial · people · 2018
- 5-Amino-1MQ slowed bladder tumor growth in miceAnimal study · mice · 2024
- MOTS-c prevented muscle atrophy, raised muscle glucose uptake in miceAnimal study · mice · 2024
- Every study on Dulaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.